Establishment Labs Holdings Reports Zero Complications for Mia Femtech™ at WSEI Symposium

Establishment Labs Showcases Groundbreaking Clinical Results for Mia Femtech™ at WSEI

Establishment Labs Holdings Inc., a leader in medical technology dedicated to enhancing women's health, particularly in breast aesthetics and reconstruction, presents compelling three-year clinical results for its Mia Femtech™ product at the 9th Annual World Symposium on Ergonomic Implants (WSEI) in Barcelona. The Mia Femtech Clinical Study, which received Institutional Review Board (IRB) approval, enrolled 100 subjects from December 2020 to April 2021. The findings are remarkable, reporting no cases of capsular contracture (Baker Grade III/IV) or implant ruptures, alongside a follow-up compliance rate of 93%. This data underscores the effectiveness of Mia Femtech™, demonstrating a 0.0% complication rate across critical measures such as infection and sensory changes, reinforcing the product's safety and efficacy profile.

CEO Juan José Chacón-Quirós emphasizes the importance of these results, asserting that they are among the best reported in breast implant studies at the three-year mark. The outcomes support the growing trend towards minimally invasive procedures, which are becoming increasingly favored in the field of breast aesthetics. Establishment Labs is poised to capitalize on this trend, particularly with the recent FDA approval of Motiva implants. The favorable clinical data provides a strong foundation for the company as it prepares to introduce Mia Femtech™ to the U.S. market, where demand for innovative breast aesthetic solutions is rapidly increasing.

The WSEI symposium, running from October 31 to November 2, 2023, gathers over 500 professionals, including plastic surgeons and researchers. This event serves as a critical platform for exchanging knowledge on advancements in breast tissue preservation and the broader implications of innovative technologies like Mia Femtech™. Establishment Labs' participation highlights its commitment to leading the dialogue on women's health and showcases its expanding portfolio, which positions the company at the forefront of the medical technology landscape.

In addition to the impressive clinical results, Establishment Labs continues to enhance its reputation within the industry by focusing on patient safety and satisfaction. As the demand for its products grows, the company remains dedicated to pushing the boundaries of what is possible in breast aesthetics and reconstruction. This commitment not only solidifies its market position but also contributes to the overall advancement of women's health solutions.